Literature DB >> 881555

Detection of circulating immune complexes in human sera by simplified assays with polyethylene glycol.

M Digeon, M Laver, J Riza, J F Bach.   

Abstract

The search for circulating immune complexes by precipitation tests using polyethylene glycol (PEG) was performed on a series of normal and pathological sera. Various factors affecting PEG precipitation were studied. Immunoglobulins and complement factors percipitated by PEG (3.5%) were quantified and their significance was discussed in relation to serum levels. The PEG test was compared to labeled C1q binding test with a fairly good correlation. The direct evaluation of the amount of C4 precipitated with IgG by 3% PEG (C4 test) provided a simpler routine assay than the C1q binding test for detecting complement-fixing immune complexes. The direct PEG test and the C4 tests gave positive results in patients with diseases generally presumed to be associated with immune complexes including systemic lupus erythematosus, acute glomerulonephritis, bacterial sub-acute endocarditis and chronic acitve hepatitis. The demonstration of HBs antigen and antibody after acid dissociation of PEG precipitates from hepatitis B seronegative sera illustrated the fact that PEG does precipitate and thus concentrates circulating immune complexes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 881555     DOI: 10.1016/0022-1759(77)90051-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  68 in total

1.  Circulating immune complexes in blood of patients with positive family history of schizophrenia.

Authors:  S Hakobyan; G Avetisyan; A Boyajyan; S Torosyan; G Khachatryan; S Tatevosyan
Journal:  Dokl Biochem Biophys       Date:  2001 Sep-Oct       Impact factor: 0.788

2.  Protein composition of circulating immune complexes in patients with periodic disease complicated or not complicated by renal amyloidosis.

Authors:  G M Mkrtchyan; A S Boyajyan; K G Karageuzyan; A A Aivazyan; S A Pashinyan; E E Nazaretyan
Journal:  Dokl Biol Sci       Date:  2002 Jul-Aug

3.  Cold-dependent activation of complement: recognition, assessment, and mechanism.

Authors:  K P Mathews; R A Mentyka; S L Chambers; T E Hugli; J H Herschbach; B L Zuraw
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

4.  Depressed primary in vitro antibody response in rheumatoid arthritis.

Authors:  P Segond; J F Delfraissy; P Galanaud; C Wallon; P Massias; J Dormont
Journal:  Clin Exp Immunol       Date:  1979-08       Impact factor: 4.330

5.  Report refuting value of immune complexes to diagnose Lyme disease is invalid.

Authors:  Michael Brunner
Journal:  Clin Vaccine Immunol       Date:  2006-02

6.  Circulating immune complexes in normal pregnant women and in some conditions complicating pregnancy.

Authors:  R D'Amelio; P Bilotta; A Pachì; F Aiuti
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

7.  Circulating immune complexes in polymyalgia rheumatica and giant cell arteritis.

Authors:  J R Park; J G Jones; G D Harkiss; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

8.  Differential precipitation of the Clq subcomponent of the first complement component (C1) by polyethylene glycol from normal human serum and sera of patients with collagen diseases.

Authors:  H Van Dijk; J Van Voorst; I G Jankowski; J W Imhof; J A Kerckhaert
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

9.  Demonstration of circulating pneumococcal immunoglobulin G immune complexes in patients with community-acquired pneumonia by means of an enzyme-linked immunosorbent assay.

Authors:  Y Holloway; J A Snijder; W G Boersma
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

10.  The role of circulating immune complexes in the glomerular disease of experimental hepatosplenic schistosomiasis.

Authors:  M Digeon; D Droz; L H Noel; J Riza; C Rieumailhol; J F Bach; F Santoro; A Capron
Journal:  Clin Exp Immunol       Date:  1979-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.